Browse the evidence

Semaglutide reduces body mass index mean by up to 16.7% in adolescents with obesity after 68 weeks.

Semaglutide can be effective for weight management in adolescents with obesity.

Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.

Practitioners can consider tirzepatide as an effective option for weight loss in adults with obesity.

Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.

Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.

Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.

Practitioners can consider retatrutide as an effective treatment option for obesity.

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.

Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.

A weight reduction of 5% or more occurred in 100% of participants who received 8 mg of retatrutide.

The 8 mg dose of retatrutide is highly effective for achieving at least a 5% weight loss in this population.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

Replacing high-glycemic-index carbohydrates with low-glycemic-index forms can improve glycemic control in diabetic patients.

Diabetic patients should consider dietary changes to include more low-glycemic-index foods for better glycemic control.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Women who increased activity after menopause (from <9 MET-h/wk at menopause to ≥9 MET-h/wk during follow-up) were at lower risk (HR, 0.90; 95% CI, 0.82-0.98).

Promoting increased physical activity after menopause may be beneficial for reducing breast cancer risk.

Obese patients with type 2 diabetes or insulin resistance benefit from a low-carbohydrate diet combined with a GLP-1 agonist.

Clinicians should consider recommending a low-carbohydrate diet with GLP-1 agonists for obese patients with type 2 diabetes.

Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.

Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.

Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.

Practitioners can consider semaglutide as an effective treatment option for weight loss in obese patients.

Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.

Tirzepatide may be considered for patients seeking substantial weight loss.

In adults with obesity, GLP-1 receptor agonists demonstrate 15% to 20% weight loss.

GLP-1 receptor agonists can be considered effective for weight management in obese adults.

Testosterone supplementation acts as a highly potent anabolic agent to skeletal muscle.

Practitioners should consider testosterone's role in muscle anabolism when advising on supplementation.

Tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% after 72 weeks of therapy.

Tirzepatide is an effective option for weight loss in adults without diabetes.